
News|Articles|April 1, 2002
Rosuvastatin: A new HMG0CoA reductase inhibitor for hypercholesterolemia (PDF)
Rosuvastatin is an investigational HMG-CoA reductase inhibitor expected to gain FDA approval later this year for treatment of hypercholesterolemia. It has significantly exceeded atorvastatin, pravastatin, and simvastatin in reducing LDL cholesterol in clinical trials. This Focus article reviews those trials as well as rosuvastatin's pharmacologic and safety profiles in an effort to delineate its likely role in cholesterol-reducing therapy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
People With Multiple Sclerosis Have Distinct Oral Microbiome, Study Shows
2
Obesity Is Now Also a Problem for People With Type 1 Diabetes
3
Data From Two Rebyota Trials Show Quality of Life Improvements | IDWeek 2025
4
Examining the Detrimental Effects of Albuminuria
5